Enclomiphene: How It Compares to Testosterone Cypionate, Enanthate, Propionate, and Pellets for Men's TRT

What Is Enclomiphene and How Does It Work?

Enclomiphene is the trans-isomer of clomiphene citrate. It occupies estrogen receptor-alpha in the hypothalamus, which tricks the brain into reading lower estrogen levels and responding with a surge in gonadotropin-releasing hormone (GnRH). That surge drives the pituitary to release more luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn signal the testes to produce testosterone and maintain sperm output. The entire axis stays intact.

Clomiphene citrate, the parent drug, contains two isomers: enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene has a much longer half-life, around 30 days, and can accumulate to produce estrogenic effects including mood changes and visual disturbances. A 2006 pharmacokinetic study published in the British Journal of Clinical Pharmacology documented this isomer-specific divergence and helped explain why racemic clomiphene produced inconsistent results in men. Enclomiphene alone delivers the hypothalamic-blocking benefit without the estrogenic buildup of zuclomiphene.

A phase II, randomized, placebo-controlled trial (N=124) by Kim et al. published in BJU International found that enclomiphene 12.5 mg and 25 mg daily raised mean morning testosterone from approximately 230 ng/dL to over 400 ng/dL within four weeks, while sperm concentration was maintained or improved compared to baseline. The trial, registered as NCT01613781, is summarized on PubMed. Testosterone cypionate 200 mg every two weeks in the same study lowered sperm concentration by approximately 94% at the same time point.

This single mechanistic difference, endogenous versus exogenous testosterone production, is the axis on which the entire enclomiphene-versus-TRT decision turns.

Enclomiphene vs. Testosterone Cypionate

Testosterone cypionate is the most widely prescribed injectable testosterone in the United States, typically formulated at 200 mg/mL in cottonseed oil and dosed at 50 to 200 mg weekly or biweekly by intramuscular or subcutaneous injection. It is FDA-approved for hypogonadism (NDA 005878) and has decades of safety data. The FDA-approved prescribing information is available on accessdata.fda.gov.

The half-life of testosterone cypionate is approximately 8 days, meaning weekly injections produce relatively stable serum testosterone levels, typically maintained between 400 and 900 ng/dL in most protocols. Biweekly dosing creates troughs that some patients describe as energy crashes.

Enclomiphene, dosed at 25 mg daily, produces steadier serum testosterone because it stimulates continuous endogenous production rather than creating the pharmacokinetic peaks and troughs of an injectable depot. In the BJU International phase II trial referenced above, the 25 mg daily enclomiphene group achieved mean testosterone levels comparable to the low-normal range seen with cypionate protocols, though the absolute ceiling is lower. Men with testosterone below 150 ng/dL from severe primary testicular failure will likely not respond adequately to enclomiphene.

Cost matters here. Compounded enclomiphene citrate runs roughly $50 to $120 per month depending on the pharmacy. Generic testosterone cypionate can cost as little as $30 to $60 per month at retail, though monitoring, syringes, and injection supplies add to the real-world cost.

A practical note on carrier oil: cottonseed oil in cypionate formulations causes injection-site reactions in a small subset of patients. Enclomiphene, being oral, eliminates that variable entirely.

Enclomiphene vs. Testosterone Enanthate

Testosterone enanthate shares the same active hormone as cypionate but uses a slightly shorter ester chain, giving it a half-life of roughly 4 to 5 days versus 8 days for cypionate. In clinical practice, many prescribers dose enanthate twice weekly (e.g., 50 mg every 3.5 days) to minimize peak-to-trough fluctuation, which can improve mood stability and reduce erythrocytosis risk. A 2004 pharmacokinetics paper in the Journal of Clinical Endocrinology and Metabolism (JCEM) confirmed that more frequent lower-dose injections of testosterone enanthate reduce hematocrit elevation compared to biweekly dosing.

Testosterone enanthate is also available in sesame oil rather than cottonseed oil, which some clinicians prefer for patients with plant-oil sensitivities. Outside the U.S., enanthate is the more common formulation, branded as Nebido (testosterone undecanoate) or Sustanon 250 in many countries.

For men choosing between enclomiphene and enanthate, the fertility question again drives the decision. Exogenous testosterone enanthate suppresses LH and FSH within days of the first injection, reducing spermatogenesis measurably within 6 weeks. The WHO Task Force on Methods for the Regulation of Male Fertility (N=271) demonstrated that weekly testosterone enanthate 200 mg produced azoospermia or severe oligospermia in the majority of participants within 6 months. That study, though designed as a contraceptive trial, quantified exactly how effective exogenous testosterone is at suppressing sperm output.

Men who have completed family planning and want the most established pharmacological profile may reasonably prefer enanthate. Men who are actively trying to conceive should use enclomiphene or other SERM-based protocols instead.

Enclomiphene vs. Testosterone Propionate

Testosterone propionate has a half-life of roughly 2 to 3 days and requires injections every other day or three times per week to maintain stable testosterone levels. That injection burden makes it far less popular than cypionate or enanthate for TRT, though it remains in use for men who want rapid dose-titration or who are sensitive to esters and prefer a short-acting option that clears quickly if therapy needs to be stopped.

Propionate is also associated with higher rates of injection-site pain relative to longer-chain esters, partly due to the short-chain propionate molecule itself and partly because many formulations use a higher-concentration carrier to keep injection volume small. A clinical review published in the Journal of Steroid Biochemistry and Molecular Biology summarized pharmacodynamic differences across testosterone esters and confirmed the injection-frequency requirement for propionate.

Enclomiphene compares favorably to propionate on convenience. Once-daily oral dosing against an every-other-day injection schedule is a substantial quality-of-life difference. For patients whose primary concern is avoiding needles or travel-related injection logistics, enclomiphene offers a straightforward advantage provided the underlying hypogonadism is secondary rather than primary.

One scenario where propionate retains a real edge: men who want a test run of testosterone therapy before committing to a longer-acting ester. A 4-to-6-week propionate trial can be stopped and cleared from the body within 10 to 14 days. Stopping enclomiphene is even simpler, with no depot to clear, though testosterone levels will return to baseline within 2 to 4 weeks as endogenous LH/FSH re-normalize.

Enclomiphene vs. Testosterone Pellets

Testosterone pellets (Testopel, 75 mg per pellet) are implanted subcutaneously in the gluteal fat via a trocar procedure performed in-office under local anesthesia. Most men receive 6 to 12 pellets per insertion, yielding a total dose of 450 to 900 mg that absorbs gradually over 3 to 6 months. The FDA-approved Testopel prescribing information indicates pellets are indicated for androgen deficiency in men and delayed puberty.

Pellets offer an unmatched convenience profile once inserted: no weekly injections, no daily pill. Serum testosterone rises within 2 to 4 weeks, typically peaking between weeks 4 and 8 and then declining toward the end of the 3-to-6-month window. Some men experience supraphysiologic levels early in the cycle, which can drive erythrocytosis and elevated estradiol.

Pellets carry procedural risks not present with enclomiphene or injectable testosterone. Reported complications include pellet extrusion (roughly 1.9% to 6.8% of insertions per observational data), infection at the insertion site, and local hematoma. A 2017 retrospective analysis in the Journal of Sexual Medicine (N=140 insertion events) documented pellet extrusion as the most common complication and found it more frequent in patients with high BMI and active exercise regimens.

Cost is also a barrier. Pellet insertion typically runs $400 to $800 per procedure out of pocket, with most insurance plans not covering it. Three insertions per year equals $1,200 to $2,400 annually before any monitoring labs.

Enclomiphene at $80 per month, roughly $960 per year, is cheaper, requires no procedure, and does not suppress the axis. Men who hate needles but are also averse to minor surgery may find enclomiphene the path of least resistance.

Who Is the Right Candidate for Enclomiphene?

Enclomiphene works only when the hypothalamic-pituitary-gonadal (HPG) axis is structurally intact and the testes retain functional capacity. Secondary hypogonadism, where low testosterone is caused by insufficient LH/FSH drive rather than testicular failure, is the required diagnosis. Typical causes include obesity (elevated aromatase converting testosterone to estradiol), hyperprolactinemia, sleep apnea, opioid use, and idiopathic hypothalamic suppression.

Labs before starting should include total testosterone (morning draw, two separate values below 300 ng/dL per Endocrine Society guidelines), free testosterone, LH, FSH, estradiol, prolactin, and a complete blood count. The 2018 Endocrine Society Clinical Practice Guideline on male hypogonadism specifies that low testosterone must be confirmed on at least two morning samples before initiating any therapy.

Men with LH and FSH already elevated (primary hypogonadism, Klinefelter syndrome, post-orchitis, post-chemotherapy) will not respond to enclomiphene because the testes cannot respond to additional gonadotropin stimulation. Those patients need exogenous testosterone.

Obesity reduces enclomiphene response. A BMI <35 is a reasonable threshold for expecting reliable response; at higher BMIs, the aromatase load may overwhelm the SERM's hypothalamic effect and estradiol can remain elevated even as testosterone rises, requiring adjunct aromatase inhibitor use.

Age also modulates response. Men over 55 with Leydig cell aging may produce less testosterone per unit of LH stimulation, meaning enclomiphene raises LH robustly but testosterone gains are blunted compared to younger men. A study in Fertility and Sterility examining clomiphene in aging men found diminishing testosterone response with advancing age, a pattern that likely extends to enclomiphene.

Dosing, Monitoring, and Titration Protocol

The standard starting dose of enclomiphene citrate is 12.5 mg orally once daily. At the 6-week mark, repeat total testosterone and estradiol. If total testosterone remains below 400 ng/dL and estradiol is not above 40 pg/mL, increase to 25 mg daily. If estradiol climbs above 40 pg/mL with testosterone still sub-therapeutic, consider adding anastrozole 0.25 mg twice weekly as a low-dose aromatase inhibitor rather than pushing the enclomiphene dose higher.

Check a CBC at 12 weeks. Enclomiphene raises endogenous testosterone, and testosterone stimulates erythropoiesis. Although the erythrocytosis risk is lower than with exogenous testosterone, it is not zero. The Endocrine Society guideline recommends withholding testosterone therapy when hematocrit exceeds 54%.

LH and FSH should normalize or rise above the lower limit of the reference range within 2 to 4 weeks on enclomiphene, confirming that the drug is engaging the hypothalamic receptor. A flat LH despite enclomiphene therapy suggests either poor absorption, pituitary pathology, or concurrent use of opioids suppressing GnRH pulsatility.

Men taking enclomiphene for fertility goals should add a semen analysis at 3 months. Sperm concentration and motility typically improve alongside testosterone, though 3 months is a minimum required for one full spermatogenic cycle.

"The advantage of enclomiphene over exogenous testosterone for secondary hypogonadism lies in the preservation of the entire hypothalamic-pituitary-testicular feedback loop," wrote the authors of the BJU International phase II trial. "This approach maintains intratesticular testosterone at concentrations substantially higher than systemic levels, a condition essential for normal spermatogenesis."

Discontinuation is straightforward. Stop the tablet. Testosterone levels return to pre-treatment baseline within 2 to 4 weeks as GnRH pulsatility returns to its baseline pattern. There is no suppression recovery period of the kind seen after stopping exogenous testosterone, which can take 3 to 18 months for full HPG axis recovery depending on duration and dose of prior TRT.

Side Effects and Safety Considerations

Enclomiphene's side effect profile is informed partly by the larger clomiphene citrate literature. Visual disturbances, described as blurred vision or light sensitivity, occurred in roughly 1 to 2% of men in clomiphene trials and are attributable largely to the zuclomiphene isomer. Because enclomiphene eliminates that isomer, visual adverse events appear less common, but any change in vision warrants immediate discontinuation and ophthalmologic evaluation.

Mood changes including irritability and anxiety occur in a subset of users, possibly due to rapid estradiol fluctuations as testosterone rises. Monitoring estradiol at 6 weeks catches this early.

Acne and scalp hair thinning are possible, driven by elevated dihydrotestosterone (DHT) from increased testosterone substrate. These risks exist with all testosterone-raising interventions and are managed with topical treatments or low-dose finasteride if clinically appropriate.

Cardiovascular safety data for enclomiphene specifically are limited compared to the decades-long dataset for testosterone cypionate. The FDA's 2015 safety communication on testosterone products required labeling changes citing possible increased cardiovascular risk with exogenous testosterone, particularly for cardiovascular events in men with pre-existing disease. Enclomiphene, by working through the endogenous axis, may not carry the same risk profile, but long-term randomized cardiovascular outcome data do not yet exist for enclomiphene.

Men with a personal or first-degree family history of thromboembolic events should discuss enclomiphene with a hematologist before starting, given that rising testosterone increases erythropoiesis and blood viscosity regardless of whether the testosterone is endogenous or exogenous.

Combining Enclomiphene with Other TRT Protocols

Some clinicians use enclomiphene adjunctively during TRT, specifically to preserve testicular size and function in men who are on testosterone cypionate or enanthate but have not yet completed family planning. The logic: exogenous testosterone suppresses LH and FSH, causing testicular atrophy and reduced intratesticular testosterone; adding a SERM partly maintains gonadotropin stimulation. Human chorionic gonadotropin (hCG) is the more established agent for this purpose, acting directly on testicular LH receptors, but enclomiphene offers oral convenience when hCG is unavailable or cost-prohibitive.

A 2005 study in the Journal of Urology (N=36) showed that clomiphene citrate adjunctive to exogenous testosterone partially maintained sperm parameters compared to testosterone alone, though sperm counts remained suppressed below baseline. Enclomiphene, as the more receptor-selective isomer, may perform similarly or better, but head-to-head data comparing enclomiphene plus TRT against hCG plus TRT are not yet published.

The most common HealthRX protocol for fertility-concerned men on exogenous testosterone is to transition from injectable testosterone to enclomiphene monotherapy 3 to 6 months before attempting conception. Transition timeline: stop testosterone cypionate or enanthate, begin enclomiphene 12.5 mg daily simultaneously, check LH/FSH and total testosterone at 6 and 12 weeks to confirm HPG axis recovery, add semen analysis at 3 months. Most men recover sperm output within 4 to 6 months, though recovery timelines of up to 18 months have been reported after multi-year high-dose exogenous testosterone use. A 2013 review in the Journal of Clinical Endocrinology and Metabolism analyzed HPG axis recovery kinetics after exogenous androgen exposure and found median time to spermatogenesis recovery of approximately 3.4 months, with full recovery taking up to 2 years in some cases.